CL2017002184A1 - Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria. - Google Patents

Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria.

Info

Publication number
CL2017002184A1
CL2017002184A1 CL2017002184A CL2017002184A CL2017002184A1 CL 2017002184 A1 CL2017002184 A1 CL 2017002184A1 CL 2017002184 A CL2017002184 A CL 2017002184A CL 2017002184 A CL2017002184 A CL 2017002184A CL 2017002184 A1 CL2017002184 A1 CL 2017002184A1
Authority
CL
Chile
Prior art keywords
sialillactose
memory function
composition
learning skills
improving learning
Prior art date
Application number
CL2017002184A
Other languages
English (en)
Inventor
Bing Wang
Zhizhong Dong
Yujie Shi
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2017002184A1 publication Critical patent/CL2017002184A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pediatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Silicon Polymers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

<p>La presente invención se refiere al uso de una composición nutricional que comprende oligosacáridos sialilados para mejorar el desarrollo cognitivo y las aptitudes de aprendizaje en mamiferos. La composición nutricional comprende 3'-sialillactosa (3'-SL) y 6'- sialillactosa (6'-SL) en una relación en peso entre 10:1 y 1:10 y, específicamente, es para usar en Ia mejora de las aptitudes de aprendizaje y/o Ia mejora Ia función de memoria en un individuo aumentando Ia concentraciôn de ácido siálico (Neu5Ac) en el cerebro de dicho individuo.</p>
CL2017002184A 2015-03-18 2017-08-28 Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria. CL2017002184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/074457 WO2016145628A1 (en) 2015-03-18 2015-03-18 Composition comprising siallyllactose for use in enhancing learning skills and memory function

Publications (1)

Publication Number Publication Date
CL2017002184A1 true CL2017002184A1 (es) 2018-05-04

Family

ID=56918404

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002184A CL2017002184A1 (es) 2015-03-18 2017-08-28 Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria.

Country Status (11)

Country Link
US (2) US11528928B2 (es)
EP (1) EP3270714B1 (es)
CN (1) CN107427057A (es)
AU (2) AU2016232084A1 (es)
BR (1) BR112017017840B1 (es)
CL (1) CL2017002184A1 (es)
MX (2) MX2017011498A (es)
MY (1) MY197396A (es)
PH (1) PH12017550052A1 (es)
RU (1) RU2770223C2 (es)
WO (2) WO2016145628A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102771814B1 (ko) * 2016-01-13 2025-02-26 주식회사 베네비오 Pgc-1알파의 발현을 증가시키는 조성물
SG10202100843TA (en) * 2016-07-28 2021-03-30 Fonterra Cooperative Group Ltd Dairy product and process
MX2019011445A (es) * 2017-05-24 2019-11-18 Nestle Sa Composicion que comprende oligosacaridos de la leche humana (hmo) para usar en la mejora de la memoria a corto plazo y otros beneficios cognitivos.
MX2019011334A (es) * 2017-05-24 2019-10-30 Nestle Sa Composicion que comprende oligofructosa (of) para usar en la mejora de la memoria a corto plazo y otros beneficios congnitivos.
WO2018215406A1 (en) * 2017-05-24 2018-11-29 Nestec S.A. A nutritional composition for use to enhance attention and/or reduce impulsivity
MX2020007192A (es) * 2017-12-01 2020-08-24 Nestle Sa Composicion fortificadora de leche humana.
WO2020001863A1 (en) * 2018-06-25 2020-01-02 Societe Des Produits Nestle S.A. Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a gabaergic function in the central nervous system
WO2020001862A1 (en) * 2018-06-25 2020-01-02 Societe Des Produits Nestle S.A. Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a serotonergic function in the central nervous system
CN108835262B (zh) * 2018-07-19 2021-08-27 澳优乳业（中国）有限公司 一种改善记忆力的调制乳粉及其制备方法
EP3934656A1 (en) * 2019-03-05 2022-01-12 Société des Produits Nestlé S.A. A nutritional composition for use to enhance executive function
EP3934657A4 (en) * 2019-03-05 2023-01-04 Glycom A/S HUMAN MILK OLYGOSACCHARIDES TO IMPROVE EXECUTION FUNCTION
WO2020259540A1 (zh) * 2019-06-25 2020-12-30 嘉必优生物技术（武汉）股份有限公司 唾液酸类化合物在制备治疗脑部退行性病变药物或营养添加剂或食品中的应用
US20230013403A1 (en) * 2019-12-09 2023-01-19 Societe Des Produits Nestle S.A. Compositions comprising human milk oligosaccharides for use in a subject to support language development
CN111387284A (zh) * 2020-04-28 2020-07-10 江苏集萃工业生物技术研究所有限公司 一种燕窝酸牛奶及其制备方法
CN114487255A (zh) * 2020-10-23 2022-05-13 内蒙古伊利实业集团股份有限公司 一种乳粉或乳清粉中唾液酸含量的检测方法
EP4313064A1 (en) * 2021-03-22 2024-02-07 Société des Produits Nestlé S.A. Human milk oligosaccharides
EP4658094A1 (en) * 2023-01-31 2025-12-10 Société des Produits Nestlé S.A. Agents, compositions, and methods for supporting motor development
CN116189909B (zh) * 2023-03-06 2024-02-20 佳木斯大学 基于推举算法的临床医学判别方法及系统
WO2025242902A1 (en) * 2024-05-24 2025-11-27 N.V. Nutricia Oligosaccharide mixture for brain development
CN119257253B (zh) * 2024-12-12 2025-03-14 飞鹤(阿鲁科尔沁旗)乳品有限公司 营养组合物辅助改善记忆能力的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701382A1 (de) * 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
US6630452B2 (en) * 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
US20060247153A1 (en) * 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
EP2544539B1 (en) 2010-03-12 2015-04-29 DSM IP Assets B.V. Maternal sialic acid supplementation
ES2601891T3 (es) * 2011-10-18 2017-02-16 Nestec S.A. Composición para su uso en crecimiento cerebral y/o desarrollo cognitivo y/o psicomotor
EP2880993A1 (en) * 2013-12-04 2015-06-10 Abbott Laboratories Method of achieving memory and learning improvement by the administration of sialic acid
US20150305384A1 (en) 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics

Also Published As

Publication number Publication date
BR112017017840A2 (en) 2018-04-10
RU2017135296A3 (es) 2019-09-10
EP3270714A1 (en) 2018-01-24
AU2020230318A1 (en) 2020-10-01
US20180064152A1 (en) 2018-03-08
WO2016145628A1 (en) 2016-09-22
RU2017135296A (ru) 2019-04-09
US11528928B2 (en) 2022-12-20
AU2016232084A1 (en) 2017-08-10
AU2020230318B2 (en) 2022-12-01
MX2017011498A (es) 2018-01-11
CN107427057A (zh) 2017-12-01
BR112017017840B1 (pt) 2022-10-25
RU2770223C2 (ru) 2022-04-14
MX2023005755A (es) 2023-06-08
WO2016146789A1 (en) 2016-09-22
MY197396A (en) 2023-06-15
EP3270714B1 (en) 2026-03-11
PH12017550052A1 (en) 2018-01-29
US20230095436A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
CL2017002184A1 (es) Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria.
CL2019002244A1 (es) Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445)
MX381600B (es) Composicion que comprende un agente de control biologico y un fungicida.
BR112018001042A2 (pt) construtos de anticorpo para flt3 e cd3
UY35472A (es) Compuestos y sus usos en la modulacion de la hemoglobina
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR088289A1 (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion
MX2016002571A (es) Regulador de ph de transduccion.
ECSP17043316A (es) Polvo de coleópteros
MX2015007933A (es) Oligosacaridos de leche humana para mejorar sintomas de estres.
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112019005328A2 (pt) composição farmacêutica líquida
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX2021015825A (es) Formulaciones de anticuerpos estables acuosas.
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
BR112018010303A2 (pt) composições e usos das mesmas
DOP2016000006A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
BR112017007375A2 (pt) composição compreendendo oligossa¬carídeos fut2 dependentes e lacto-n-neotetraose para uso na promoção do desenvolvimento e da cognição cerebral
BR112015020904A2 (pt) microrganismos e métodos para produção de butadieno e compostos relacionados por assimilação de formiato
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
PE20150908A1 (es) Fortificador de la formula
MX2015012341A (es) Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.